



Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 11th December 2023

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 25th September 2023 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Sodium Tetradecyl Sulfate 0.5% and 1% Injection (Fibroven®)**

Requested by: Vascular Surgery

Indication: Sclerotherapy of Varicose Vein

Proposal: Add to the formulary

Rational: This drug will be prescribed for patients referred for the new Endovenous Laser Treatment (EVLT) for Varicose Veins provided by Ms Clough and Mr Glasgow as part of a service which will operate twice a week in the Treatment Centre.

Cost: Dependent on vial strength used; 0.5% - 2mL ampoule - £3.79 + VAT and 1% - 2mL ampoule - £4.52 + VAT

Likely to treat: 150 patients per year at CW site. Estimated £3,390 + VAT per annum.

Outcome: Approved for addition to the Trust Formulary

- **Eye drops for Cornea Clinic**

Requested by: Ophthalmology

Indication: Eye drops for use in line with their licensed use

Proposal: Add the following eye drops to the formulary for their licensed indications for prescribing in new Cornea Clinic at CWH site:

Antibacterials:

- Moxifloxacin 0.5%
- Azithromycin 1.5%

Anti-inflammatory agents

- Ketotifen 250mcg/ml
- Olopatadine 0.1%

Corticosteroids

- Hydrocortisone 3.35mg/ml

Antiseptic agent

- Propamidine 0.1%

Rational: These eye drops are required to be available for prescribing to patients attending the new Cornea Clinic due to open at CWH Site.

Cost: Various

Likely to treat: Various



Included on the NWL JF: Moxifloxacin, Olopatadine & Ketotifen
Not included on the NWL JF: Hydrocortisone, Azithromycin, Propamidine
All included on Pan London Ophthalmology Formulary
Outcome: Approved for addition to the Trust Formulary

Removals

- **Lixisenatide 10mcg and 20mcg Injection (Lyxumia®)**

Discontinued by the manufacturer

Outcome: Approved for discontinuation from the Trust Formulary

- **Calcium Syrup (Alliance) 102 mg/5mL**

Discontinued by the manufacturer

Outcome: Approved for discontinuation from the Trust Formulary

- **Sandocal 400 effervescent Tablet (10mmol/Tablet)**

Discontinued by the manufacturer

Outcome: Approved for discontinuation from the Trust Formulary

- **Co-Amoxiclav 400/57mg/5ml Liquid**

Removal from formulary requested by Microbiology on account of patient safety

Outcome: Approved for discontinuation from the Trust Formulary

- **Topiramate (Sugar Free) Oral Suspension (25mg/5mL)**

Discontinued by the manufacturer - See below

Outcome: Approved for discontinuation from the Trust Formulary

Ex-Panel

- **Calvive 1000 effervescent Tablet (25mmol/Tablet)**

New product that is being procured as an alternative to Sandocal 400 effervescent tablet

Outcome: Approved for addition to the Trust Formulary

- **Testosterone 20mg/g Transdermal Gel (23mg per actuation) (Testavan®)**

Requested by Endocrinology as an alternative preparations during manufacturer shortages of Tostran® and Testogel® Gel.

Added to NWL Joint Formulary in October.

Cost:

Testavan: £25.22

Tostran: £28.63

Testogel: £30.50

Outcome: Approved for addition to the Trust Formulary

- **Topiramate (Sugar Free) Oral Suspension (10mg/mL)**

Requested by Paediatric Neurology as an alternative formulation to tablets that are currently included on the formulary to support dose administration to paediatric patients.

Liquid of strength 25mg/5ml (5mg/ml) is included on the formulary but is no longer commercially available. To be replaced with the 10mg/ml strength suspension.

Cost of 150ml bottle - £260 ex. VAT

Cost of 50mg dose - Liquid £8.67

Cost of 50mg dose - Tablet £0.41

Outcome: Approved for addition to the Trust Formulary

- **Perampanel (Sugar Free) Oral Suspension (0.5mg/mL)**

Requested by Paediatric Neurology as an alternative formulation to tablets that are currently included on the formulary to support dose administration to paediatric patients



Cost of 340ml bottle - £141 ex. VAT

Cost of 4mg dose - Liquid £3.32

Cost of 4mg dose - Tablet £4.57

Outcome: Approved for addition to the Trust Formulary

NICE Approved drug applications

- Nil

Pharmacoeconomic Board requests

- **Nitazoxanide (UMP) for Enterovirus Meningitis**

Approved by the Pharmacoeconomic Board on 07/11/2023

Outcome: Noted

- **Favipiravir (UMP) for Enterovirus Meningitis**

Approved by the Pharmacoeconomic Board on 07/11/2023

Outcome: Noted

- **Pocapavir (UMP) for Enterovirus Meningitis**

Approved by the Pharmacoeconomic Board on 08/11/2023

Outcome: Noted

- **Ipilimumab and Nivolumab for Kaposi Sarcoma**

Approved by the Pharmacoeconomic Board on 08/11/2023

Outcome: Noted

- **Ustekinumab (Dose Escalation) for Crohn's Disease**

Approved by the Pharmacoeconomic Board on 14/11/2023

Outcome: Noted

- **Infliximab for sight threatening Rheumatoid Scleritis**

Approved by the Pharmacoeconomic Board on 21/11/2023

Outcome: Noted

- **Lenalidomide for Primary Plasma Cell Leukaemia**

Approved by the Pharmacoeconomic Board on 27/11/2023

Outcome: Noted

4.2 Trust Medicines Policy

- Nil

4.3 Medicines Optimisation

- **Trust Medicines Optimisation Annual Report 2022-2023**

Medicines optimisation encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.

This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2022-23 year and reports on results of external assessments.

Summary

- Trust Medicines Group meeting x 5 held



- Formulary applications: 33 x applications - 9 x full submissions, 11 x ex-panel requests and 13 x Individual Funding Requests (approved by Pharmacoeconomic Board). All reviewed and approved
- Trust Medicines Policy: 9 x updates approved
- NICE Technology Appraisals: 93 x NICE TAs noted and actioned; 5 HSTs noted
- Patient Group Directions: 31 x PGDs approved - 29 x existing PGDs and 2 x newly drafted. By March 2023 there were 91 PGDs in use in the Trust.
- IV Immunoglobulin: 148 x issues for immunoglobulin for new patients approved across both sites
- Chemotherapy: £170k drug savings (QI wastage project, Biosimilar switches and outsourcing of Bortezomib)
- Antimicrobial Stewardship: CQUINs remain suspended since Covid-19 Pandemic but AMS Team continue to undertake monitoring against historic targets:
 - Improvement in diagnosis and treatment of urinary tract infections: Trust exceeded the minimum target (60%) with compliance identified as 85%, 77%, 77% for the first 3 quarters. (Top 10% of reporting Trusts)
 - Reducing total antibacterial usage across the Trust: Significant reduction (>10%) over the last financial year from baseline 2017
 - Reducing quinolones and carbapenem usage: >25% overall reduction at CWFT versus an 4% increase with London peers
 - Optimising antifungal usage: Total antifungal costs have reduced from £475,000 in 2018/19 to £235,000 in 2022/23 representing a >50% saving in drug costs.
- 4 x Guidelines updated; 6 x Audits undertaken; 9 x publications 3 x posters and 1 x presentation at conference
- VTE Prevention: The Trust did not achieve the national target of $\geq 95\%$ (Achieved: 92.58%) for VTE risk assessment completion for adult patients on admission to hospital in 2022-23. Increased optimisation of electronic VTE risk assessment with Cerner functionality; 24 x Guidelines updated; 3 x Audits undertaken
- Homecare: As at March 2023, 3,351 patients enrolled and receiving medicines via Homecare services.
- Medication Safety: A total of 1,649 medicine-related incidents reported across the Trust representing a 17% increase in incident reporting across both hospital sites. 2 x NHS England Alerts actioned; 8 x MSG meetings held; 11 x Medication Safety Bulletins published
- Controlled Drugs: 415 incidents related to CDs, 71 incidents related to unaccounted for CDs of which 9 x incidents reports to NHS England
- Non-Medical Prescribers: By March 2023 there were 112 x NMPs in post and on the Trust NMP Register
- EPMA: EMPA on AEC went live in May 2022 and on NICU in October 2022
- Clinical Trials: 65 x active Clinical Trials across both hospital sites
- Medicines related cost savings: £250k In-tariff
- In total 9 x clinical audits undertaken
- Medicines Information: 976 x enquiries received and managed (803 from HCPs and 173 from members of the public)
- Innovation projects that were initiated included Guided Picking and Electronic Controlled Drug ordering

Outcome: Noted

- **Guideline for medical and pharmacy staff managing patients on lithium therapy at Chelsea and Westminster Hospital (CWH Site)**

New guideline for the management of patients admitted taking Lithium therapy - CWH Site
Written in collaboration with the CNWL Liaison Psychiatry Team

Outcome: Approved but group have asked that both site policies are amalgamated into a single policy for use in the Trust.

- **Guideline for medical and pharmacy staff managing patients on lithium therapy at Chelsea and Westminster Hospital (WMUH Site)**

New guideline for the management of patients admitted taking Lithium therapy - WMUH Site
Written in collaboration with Hounslow Liaison Psychiatry Team



Outcome: Approved but group have asked that both site policies are amalgamated into a single policy for use in the Trust

4.4 NICE Technical Appraisals and Guidance

a) NICE Technology Appraisals published

20 TA appraisals published since previous TMG meeting

TA913 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (06/09/2023)

Formulary status / Action

Action: Nil - Not applicable as condition not treated at CWFT

TA914 Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (20/09/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: ___patients per year

Numbers likely to treat at WMUH site: 0 patient per year

TA915 - Pegunigalsidase alfa for treating Fabry disease (04/10/2023)

Formulary status / Action

Not included on the formulary

Action: Nil - Not applicable as condition not treated at CWFT

TA916 - Bimekizumab for treating active psoriatic arthritis (04/10/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 5 patients per year

Numbers likely to treat at WMUH site: ___patient per year

TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (25/10/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: ___ patient per year

Numbers likely to treat at WMUH site: 10-12 patients per year

TA918 - Bimekizumab for treating axial spondyloarthritis (11/10/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 5 patients per year

Numbers likely to treat at WMUH site: ___ patient per year

TA919 - Rimegepant for treating migraine (18/10/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 75-100 patients per year

Numbers likely to treat at WMUH site: 75-100 patients per year

TA920 - Tofacitinib for treating active ankylosing spondylitis (18/10/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 0-1 patient per year

Numbers likely to treat at WMUH site: ___patient per year

TA921 - Ruxolitinib for treating polycythaemia vera (18/10/2023)

Formulary status / Action



Included on the formulary for another indication

Numbers likely to treat at CWH site: ___ patient per year

Numbers likely to treat at WMUH site: 6 patients per year

TA922 - Daridorexant for treating long-term insomnia (18/10/2023)

Formulary status / Action

Not included on the formulary

Add to the formulary following receipt of an application form from the Care of the Elderly Department

TA923 - Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (19/10/2023)

Formulary status / Action

Nil - Terminated Appraisal

TA924 - Tirzepatide for treating type 2 diabetes (25/10/2023)

Formulary status / Action

Not included on the formulary

Add to the formulary following receipt of an application form from the Endocrinology Department.

TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis (25/10/2023)

Formulary status / Action

Not included on the formulary

Add to the formulary following receipt of an application form from the Gastroenterology Department.

TA926 - Baricitinib for treating severe alopecia areata (25/10/2023)

Formulary status / Action

Nil - Not recommended

TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (17/10/2023)

Formulary status / Action

Not included on the formulary

Add to the formulary following receipt of an application form from the Haematology Department.

TA928 - Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (01/11/2023)

Formulary status / Action

Nil - Not recommended

TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (01/11/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 75 patients per year

Numbers likely to treat at WMUH site: 75 patients per year

TA930 - Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (15/11/2023)

Formulary status / Action

Nil - Not recommended

TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia (22/11/2023)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: ___ patient per year

Numbers likely to treat at WMUH site: 2-4 patients per year



TA932 - Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Terminated appraisal) (23/11/2023)

Formulary status / Action

Nil - Terminated Appraisal

b) NICE Highly Specialised Technology Appraisals published since last meeting

1 HST appraisal published since previous TMG meeting

HST28 Birch bark extract for treating epidermolysis bullosa (20/09/2023)

Not applicable to CWFT

4.5 Items for noting

- **Quarterly Controlled Drug Summary Report - Q2 2023/24**

Quarterly Controlled Drug Summary Report for Q2 2023/24

Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q2 2023/24**

Quarterly CD Accountable Officer Report for Q2 2023/24

Outcome: Noted

- **Medication Safety Bulletin: World Thrombosis Day**

Medication Safety Bulletin relating to World Thrombosis Day

Outcome: Noted

- **Medication Safety Bulletin: Adrenal Insufficiency**

Medication Safety Bulletin relating to Adrenal Insufficiency

Outcome: Noted

- **MHRA Drug Safety Update - September 2023**

MHRA update for September 2023

Outcome: Noted

- **MHRA Drug Safety Update - October 2023**

MHRA update for October 2023

Outcome: Noted

- **MHRA Drug Safety Update - November 2023**

MHRA update for November 2023

Outcome: Noted

4.6 Meeting minutes for noting

- **Medication Safety Group meeting minutes - September 2023**

Minutes from Medication Safety Group Meeting held September 2023

Outcome: Noted

- **Medication Safety Group meeting - Terms of Reference - June 2023**

Medication Safety Group Meeting - Terms of Reference - June 2023

Outcome: Noted

- **Medicines Optimisation Group - Action Log - October 2023**

Medication Optimisation Group - Action Log - October 2023

Outcome: Noted



5. Any other business

Nil

6. Date of next meeting

Next meeting

Date 11th December 2023

Time: 8am-9am

Location: via Teams